Bone Metastases in Endocrine Cancers: Advances in Diagnosis, Treatment, and Prevention

The management of bone metastases in endocrine-related cancers is a continually evolving field, marked by significant challenges and advances that affect patient outcomes. These secondary cancer developments complicate endocrine cancer treatments, urging ongoing research to refine and innovate therapeutic approaches. The recent advancements, especially in endocrine therapies and surgical techniques, have improved prognoses for patients with metastatic bone disease. However, disparities in life expectancy among patients with different endocrine cancers, as well as across various treatment epochs, demonstrate the persistent gaps in our current understanding.

This Research Topic aims to delve deeper into the evolving dynamics of life expectancy and treatment efficacy in MBD within the sphere of endocrine oncology. It seeks to assess the effectiveness of both established and novel diagnostic and therapeutic options, focusing on their impact on patient outcomes and quality of life. There is a particular interest in understanding the interplay between primary endocrine cancers and survival rates following MBD treatments, evaluating new scoring systems like Bone-RADS for their clinical utility, and exploring innovative, less invasive treatment modalities that could enhance patient care.

To gather further insights into these critical areas, we welcome articles addressing, but not limited to, the following themes:

• Endocrine signaling and hormone-driven cancers influencing bone metastasis progression.
• Comparative studies on novel endocrine-targeted therapies versus traditional treatments for MBD.
• Evaluations of advanced imaging techniques and the Bone-RADS scoring system in detecting and monitoring bone metastases
• Identification and validation of biomarkers predicting bone metastasis risk and treatment response in endocrine cancers.

Through this focused exploration, the Topic seeks to advance the understanding and management of bone metastases in patients suffering from endocrine cancers, aiming to significantly enhance patient care and outcomes.